Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 601-610

  Rossini, Maurizio ^a   Lello, Stefano ^b   Sblendorio, Ignazio ^c   Viapiana, Ombretta ^a   Fracassi, Elena ^a   Adami, Silvano ^a   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c Medical Coach Italia Center   (Italy)

Author keywords

Bone mineral density; Bone turnover markers; Climacteric symptoms; Menopause; Tissue selective estrogen complex

Indexed keywords

BAZEDOXIFENE; CARBOXY TERMINAL TELOPEPTIDE; CONJUGATED ESTROGEN; ESTROGEN; OSTEOCALCIN; PLACEBO; RALOXIFENE; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BLEEDING; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; LUMBAR SPINE; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; SPINE FRACTURE; SWEATING; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VAGINA DISEASE; VAGINAL DRYNESS; VAGINAL IRRITATION; VENOUS THROMBOEMBOLISM; BONE REMODELING; CLINICAL TRIAL (TOPIC); DEFICIENCY; DRUG EFFECTS; FEMALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; VERY ELDERLY;

AGED, 80 AND OVER; BONE DENSITY; BONE REMODELING; CLINICAL TRIALS AS TOPIC; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84880738223     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S47807     Document Type: Review

References (62)

1. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol. 2007;211(2):173-180.
2. Vagenakis AG. Endocrine aspects of menopause. Clin Rheumatol. 1989;8(Suppl 2):48-51.
3. Rödström K, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause. 2002;9(3):156-161.
4. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health. 1985;8(3):261-268.
5. Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(2):107-110.
6. Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas. 2005;52(3-4):264-276.
7. Bjarnason NH, Alexandersen P, Christiansen C. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone. 2002;30(4):637-642.
8. Nilas L, Christiansen C. The pathophysiology of peri-and postmenopausal bone loss. Br J Obstet Gynaecol. 1989;96(5):580-587.
9. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995;122(1):9-16.
10. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab. 2010;95(8):3569-3577.
11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
12. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783-789.
13. Parente L, Uyehara C, Larsen W, Whitcomb B, Farley J. Long-term impact of the women's health initiative on HRT. Arch Gynecol Obstet. 2008;277(3):219-224.
14. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
15. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001;949:317-326.
16. Evista® (raloxifene hydrochloride) tablet [prescribing information]. Indianapolis: Eli Lilly and Company; 2007.
17. Taylor HS. Designing the ideal selective estrogen receptor modulator-an achievable goal? Menopause. 2009;16(3):609-615.
18. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15(10):984-992.
19. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):561-570.
20. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146(9):3999-4008.
21. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol. 2008;287(1-2):40-46.
22. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149(12):6084-6091.
23. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009;150(4):1897-1903.
24. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv. 2005;5(6):343-357.
25. Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs. 2004;5(10):1086-1093.
26. Chandrasekaran A, Ermer J, McKeand W, et al. Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women. Clinical Pharmacology and Therapeutics. 2003;73:47.
27. Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, Scatina J. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos. 2009;37(6):1219-1225.
28. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001;44(11):1654-1657.
29. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol. 2005(6);105:1397-1404.
30. Boudes P, Ronkin S, Korner P, et al. Effects of bazedoxifene TSE-424, a novel tissue selective estrogen receptor modulator SERM, on the incidence of breast pain [abstract]. Osteoporos Int. 2003;14(Suppl 7):S14.
31. Ronkin S, Baracat E, Roma L, et al. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. Presented at: Endocrine Society 83rd Annual Meeting; June 20-23, 2001; Denver, CO.
32. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23(4):525-535.
33. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923-1934.
34. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause. 2009;16(6):1102-1108.
35. Silverman SL, Chines AA, Kendler DL, et al; Bazedoxifene Study Group. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2012;23(1): 351-363.
36. Palacios S, Silverman S, Levine AB, et al. Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study [abstract]. Climacteric. 2011;14(Suppl 1):59-60.
37. Bachmann G, Crosby U, Feldman RA, Ronkin S, Constantine GD. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. Menopause. 2011;18(5):508-514.
38. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
39. Pickar JH. Tissue selective estrogen complex: a new paradigm for menopausal therapy. Menopausal Med. 2008;16(1):S10-S13.
40. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3): 1018-1024.
41. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril. 2009;92(3):1025-1038.
42. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92(3):1039-1044.
43. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92(3):1045-1052.
44. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116-1124.
45. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281-289.
46. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric. 2013;16(3):338-346.
47. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75(6):1065-1079.
48. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women [abstract]. Menopause. 2010;17(6):1237-1238.
49. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63(4):329-335.
50. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) [abstract]. Menopause. 2010;17(6):1219.
51. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132-140.
52. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol. 1997;11(5):341-355.
53. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas. 1993;17(3): 191-196.
54. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.
55. Smith DC, Prentice R, Thompson DJ, Hermann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293(23):1164-1167.
56. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103-115.
57. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668-2676.
58. Adami S, Bianchi G, Brandi ML, et al; BONTURNO study group. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int. 2008;82(5):341-347.
59. Bauer DC, Black DM, Garnero P, et al; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19(8):1250-1258.
60. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18(6):1051-1056.
61. Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D. Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother. 2013;14(10):1371-1381.
62. Rossini M, Bianchi G, Di Munno O, et al; Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6): 914-921.